Results 71 to 78 of about 30,968 (78)

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers

Cancer Cell
Xiufeng Pang, Xinyi Shi, Guizhen Zhou
exaly  

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism

Cancer Cell, 2018
Kenneth H Pearce, Haiyong Han, Prson Gautam   +2 more
exaly  

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial

Annals of Oncology, 2015
Roberto Labianca, Mirko Marabese, Valter Torri   +2 more
exaly  

A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

Annals of Oncology, 2011
Dongyun Yang, E K Rowinsky
exaly  

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

Annals of Oncology, 2008
Nicola Personeni, Hubert Piessevaux, J -L van Laethem   +2 more
exaly  

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

Cancer Cell
Xinyuan Tong, Hongbin Ji, Juntao Gao
exaly  

Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer

Cancer Cell
Shiqi Mao, Caicun Zhou, Wanying Wang
exaly  

KRAS inhibitors: resistance drivers and combinatorial strategies

Trends in Cancer
Bjoern Papke, Tamara Isermann, Christine Sers   +2 more
exaly